Overview of Methazolamide
Methazolamide, with the NDC code 62559-0240, is a carbonic anhydrase inhibitor manufactured by ANI Pharmaceuticals, Inc. It is primarily used in the treatment of glaucoma, epilepsy, and altitude sickness.
Current Market Status
Availability and Label Status
Methazolamide, under the NDC code 62559-0240, is currently available and has not been marked for deletion or discontinuation by ANI Pharmaceuticals, Inc.[1].
Market Competition
The market for carbonic anhydrase inhibitors is relatively niche but competitive. Generic versions of these drugs, including methazolamide, often face competition from other generic and branded products. However, the specific market dynamics for methazolamide are less affected by the broader trends in high-cost therapies and more by the demand for generic medications[3].
Price Trends and Projections
General Pharmaceutical Price Inflation
According to Vizient's summer Pharmacy Market Outlook, the overall drug price inflation rate for pharmaceuticals in 2025 is projected to be 3.81%. This inflation is driven by various factors, including the expanding indications of previously approved medications and the introduction of high-cost cell and gene therapies[2].
Specific Price Considerations for Methazolamide
Given that methazolamide is a generic drug, its pricing is generally more stable compared to branded or newly approved medications. However, it is still subject to the broader pharmaceutical price inflation trends.
International Price Comparisons
The U.S. pharmaceutical market, including generic drugs like methazolamide, is characterized by higher prices compared to other regions. The average price per unit in the U.S. is significantly higher than in the OECD and the rest of the world, which could influence pricing strategies and market dynamics[4].
Factors Influencing Price
Regulatory and Market Pressures
Pricing and access to drugs are significant concerns for the life sciences industry. Executives expect these issues to impact their strategies in 2025, with nearly half anticipating a significant impact. This could lead to pricing adjustments as companies navigate regulatory and market pressures[3].
Patent and Exclusivity Issues
The biopharma industry is facing a substantial loss of exclusivity due to expiring patents, which could drive interest in mergers and acquisitions. However, since methazolamide is a generic drug, it is less affected by patent expirations compared to branded products[3].
Technological and Innovative Trends
The integration of technologies like gen AI and increased use of data are expected to boost operational efficiencies and drive innovations. While these trends may not directly impact the pricing of generic drugs like methazolamide, they could influence the broader pharmaceutical market and indirectly affect pricing strategies[3].
Market Outlook for 2025
Overall Pharmaceutical Market
The life sciences industry is poised for significant transformation in 2025, driven by digital advancements and scientific innovations. Despite competitive pressures and business volatility, most global life sciences executives are optimistic about the future. This optimism, however, does not necessarily translate to stable or decreasing prices for pharmaceuticals[3].
Specific Outlook for Methazolamide
Given the projected 3.81% drug price inflation rate, it is likely that the price of methazolamide will increase, albeit at a rate that is generally lower than that of newer, branded medications. The stability of generic drug prices, combined with the broader market trends, suggests a moderate price increase for methazolamide in 2025.
Key Takeaways
- Availability: Methazolamide (NDC: 62559-0240) is currently available and not marked for deletion.
- Price Inflation: The overall pharmaceutical price inflation rate for 2025 is projected at 3.81%, which may influence the pricing of methazolamide.
- Market Dynamics: The drug faces competition from other generic and branded products but is less affected by high-cost therapies and patent expirations.
- Regulatory and Market Pressures: Pricing and access issues are significant concerns, but their impact on generic drugs like methazolamide is moderate.
- Technological Trends: While not directly impacting methazolamide, technological advancements could influence broader market strategies.
FAQs
Q: What is the current status of Methazolamide (NDC: 62559-0240)?
A: Methazolamide is currently available and has not been marked for deletion or discontinuation by ANI Pharmaceuticals, Inc.
Q: What is the projected price inflation rate for pharmaceuticals in 2025?
A: The projected overall drug price inflation rate for pharmaceuticals in 2025 is 3.81% according to Vizient's summer Pharmacy Market Outlook.
Q: How does the U.S. pharmaceutical market compare to other regions in terms of pricing?
A: The U.S. pharmaceutical market has significantly higher prices compared to the OECD and the rest of the world, with prices in the U.S. being 5.5 times those in the OECD and 7.7 times those in the rest of the world.
Q: What factors are influencing the pricing of pharmaceuticals in 2025?
A: Factors include expanding indications of previously approved medications, introduction of high-cost cell and gene therapies, regulatory and market pressures, and technological advancements.
Q: How is the life sciences industry expected to transform in 2025?
A: The industry is expected to undergo significant transformation driven by digital advancements and scientific innovations, despite competitive pressures and business volatility.
Sources
- ANI Pharmaceuticals, Inc. - List of Drugs - NDC Labeler/Manufacturer. Find a Code.
- Vizient projects drug price inflation at 3.81%. Vizient Inc.
- 2025 life sciences outlook. Deloitte Insights.
- ISSUE BRIEF - ASPE. ASPE.
